47 results on '"Thomas-Schoemann, A."'
Search Results
2. Prevalence of drug–drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management
3. Letter to the editor regarding the paper by A. Boileve et al.: Safety of direct oral anticoagulants in patients with advanced solid tumors receiving anti‑VEGF agents: a retrospective study.
4. Pharmacokinetics and Pharmacodynamics of Once-daily Prolonged-release Tacrolimus in Liver Transplant Recipients
5. Pazopanib pharmacokinetically guided dose optimization in three cancer patients with gastrointestinal resection.
6. Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients
7. Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences
8. Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report.
9. Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients
10. Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old
11. Drug interactions with solid tumour-targeted therapies
12. Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study
13. ADAM9 expression promotes an aggressive lung adenocarcinoma phenotype
14. Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma
15. Cardiac toxicity associated with pharmacokinetic drug–drug interaction between crizotinib and sofosbuvir/velpatasvir: A case report.
16. Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients
17. Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand–foot syndrome (HFS)
18. Soluble VEGFR-1: A new biomarker of sorafenib-related hypertension (i.e., sorafenib-related is the compound adjective?)
19. Functional and Clinical Evidence of the Influence of Sorafenib Binding to Albumin on Sorafenib Disposition in Adult Cancer Patients
20. PHARMACEUTICAL CONSULTATIONS DEDICATED TO DIRECT ORAL ANTICOAGULANTS FOR CANCER PATIENTS: A SINGLE-CENTRE PROSPECTIVE STUDY.
21. Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients.
22. Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study.
23. Bystander effect of vinorelbine alters antitumor immune response
24. Tumor invasion induced by oxidative stress is dependent on membrane ADAM 9 protein and its secreted form
25. Individual dosing regimen of mycophenolate mofetil in lupus patients: Comment on the article by Zahr et al
26. ECONOMIC IMPACT OF THE CLINICAL PHARMACIST ON THE REDUCTION OF DRUG-RELATED PROBLEMS BEFORE THE INITIATION OF AN ANTI-TUMOUR TREATMENT -- A PROSPECTIVE MULTICENTRE TRIAL.
27. Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.
28. Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib.
29. ADAM9 expression promotes an aggressive lung adenocarcinoma phenotype.
30. Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma.
31. Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France.
32. An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients.
33. Arsenic Trioxide Exerts Antitumor Activity through Regulatory T Cell Depletion Mediated by Oxidative Stress in a Murine Model of Colon Cancer.
34. Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines).
35. Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study.
36. Is there an Exposure–Response Relationship for Nivolumab in Real-World NSCLC Patients?
37. Letter to the editor regarding the paper by Loquai C et al. ‘Use of complementary and alternative medicine: a multicenter cross-sectional study in 1089 melanoma patients’.
38. Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab.
39. Benefit of therapeutic drug monitoring to disclose pharmacokinetic interaction between sunitinib and calcium channel blocker.
40. A new strategy to target regulatory T cells in solid tumors.
41. The impact of body composition parameters on severe toxicity of nivolumab.
42. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients
43. Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients.
44. A HPLC-fluorescence method for the quantification of abiraterone in plasma from patients with metastatic castration-resistant prostate cancer.
45. 1549P Pazopanib exposure in advanced soft tissue and bone sarcoma: A pharmacokinetic/pharmacodynamic analysis.
46. 451PPharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma.
47. 1632P_PRCharacterizing the risk of drug-drug interactions in sarcoma treated patients: Role of pharmacist integration.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.